NASDAQ:NTGN - Neon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.04 -0.13 (-2.51 %)
(As of 01/18/2019 08:44 AM ET)
Previous Close$5.17
Today's Range$4.95 - $5.30
52-Week Range$4.87 - $16.23
Volume102,531 shs
Average Volume116,374 shs
Market Capitalization$146.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Neon Therapeutics, Inc. has a clinical trial collaboration with Natera, Inc. to assess the treatment response to personal cancer vaccine. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive NTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTGN
CUSIPN/A
Phone617-337-4701

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-47,530,000.00

Miscellaneous

Employees84
Market Cap$146.38 million
OptionableNot Optionable

Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions

What is Neon Therapeutics' stock symbol?

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) posted its quarterly earnings results on Monday, November, 12th. The company reported ($0.67) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.79) by $0.12. View Neon Therapeutics' Earnings History.

When is Neon Therapeutics' next earnings date?

Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 11th 2019. View Earnings Estimates for Neon Therapeutics.

What price target have analysts set for NTGN?

3 analysts have issued twelve-month price objectives for Neon Therapeutics' stock. Their forecasts range from $18.00 to $23.00. On average, they expect Neon Therapeutics' stock price to reach $20.25 in the next twelve months. This suggests a possible upside of 301.8% from the stock's current price. View Analyst Price Targets for Neon Therapeutics.

What is the consensus analysts' recommendation for Neon Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neon Therapeutics.

Has Neon Therapeutics been receiving favorable news coverage?

News stories about NTGN stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neon Therapeutics earned a news impact score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Neon Therapeutics' key competitors?

Who are Neon Therapeutics' key executives?

Neon Therapeutics' management team includes the folowing people:
  • Mr. Hugh O'Dowd, Pres, CEO & Director (Age 53)
  • Dr. Eric S. Lander, Founder & Director (Age 61)
  • Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 36)
  • Dr. Richard Gaynor, Pres of R&D (Age 68)
  • Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer

When did Neon Therapeutics IPO?

(NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.

When did the company's lock-up period expire?

Neon Therapeutics' lock-up period expired on Monday, December 24th. Neon Therapeutics had issued 6,250,000 shares in its public offering on June 27th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Neon Therapeutics?

Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neon Therapeutics' stock price today?

One share of NTGN stock can currently be purchased for approximately $5.04.

How big of a company is Neon Therapeutics?

Neon Therapeutics has a market capitalization of $146.38 million. Neon Therapeutics employs 84 workers across the globe.

What is Neon Therapeutics' official website?

The official website for Neon Therapeutics is http://www.neontherapeutics.com.

How can I contact Neon Therapeutics?

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]


MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: What are Bollinger Bands?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel